Innovent Biologics, Inc. (HKG:1801)
98.05
+2.15 (2.24%)
Sep 30, 2026, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 8,754 employees as of June 30, 2026. The number of employees increased by 1,252 or 16.69% since the number was reported on December 31, 2025.
Employees
8,754
Change
1,252
Growth
16.69%
Revenue / Employee
2.07M HKD
Profits / Employee
162.53K HKD
Market Cap
170.70B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 8,754 | 1,252 | 16.69% |
| Dec 31, 2025 | 7,502 | 1,843 | 32.57% |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| WuXi Biologics | 14,705 |
| BeOne Medicines AG | 12,000 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Akeso | 4,082 |
| RemeGen | 3,145 |
| Shanghai Junshi Biosciences | 3,055 |
Innovent Biologics News
- 2 days ago - Innovent Reports Updated Phase 1 Data For IBI3003 In Relapsed/Refractory Multiple Myeloma - Nasdaq
- 3 days ago - Innovent's Jaypirca Gets Expanded NMPA Approval For CLL/SLL - Nasdaq
- 3 days ago - Innovent Biologics announces China NMPA approves Jaypirca for new indication - TheFly
- 3 days ago - Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy - PRNewsWire
- 3 days ago - Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down - Nasdaq
- 3 days ago - Innovent Biologics announces expansion of global Phase 3 MarsLight-11 trial - TheFly
- 8 days ago - Altruist Biologics' Suzhou Facility Clears EMA GMP Inspection - Nasdaq
- 8 days ago - Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting - PRNewsWire